Plasma Cell Disorders Clinical Trial
Official title:
Gut Microbiome Studies in Patients With POEMS Syndrome and Other Plasma Cell Disorders
A Study to Evaluate Gut Microbiome with POEMS Syndrome and Other Plasma Cell Disorders
The characteristics and role of gut microbiome rare plasma cell disorders- POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes) and amyloid light-chain (AL) amyloidosis, have not been explored; and their pathophysiology is quite elusive. To help understand rare plasma cell disorders and its association with gut microbiome, the investigators will study the stool samples of newly diagnosed POEMS patients and AL amyloidosis and compare it with patients with newly diagnosed monoclonal gammopathy of undetermined significance and multiple myeloma as well as healthy controls. Moreover, gut microbiome in newly diagnosed POEMS patients will be compared to POEMS patients in remission. It is the overall hypothesis that in POEMS patients the gut microbiome signature will differ between active disease (at diagnosis) and inactive disease (in remission), and the gut microbiome in POEMS patients will be different from patients with other plasma cell disorders and healthy controls. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02566265 -
Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients
|
Phase 2 | |
| Completed |
NCT01362985 -
Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry for Off-Label Transplant Use of Plerixafor
|
Phase 4 | |
| Not yet recruiting |
NCT06286215 -
Registry of Patients With Plasma Cell Disorders
|